Lithium Chloride Therapy Fails to Improve Motor Function in a Transgenic Mouse Model of Machado-Joseph Disease

Cerebellum

Volumn 13, Issue 6, 2014, Pages 713-727

  Duarte Silva, Sara ^a,b   Neves Carvalho, Andreia ^a,b   Soares Cunha, Carina ^a,b   Teixeira Castro, Andreia ^a,b   Oliveira, Pedro ^c   Silva Fernandes, Anabela ^a,b   Maciel, Patrícia ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Autophagy; Lithium; Polyglutamine; Spinocerebellar ataxia; Therapy; Triplet repeats

Indexed keywords

BECLIN 1; CELL PROTEIN; LITHIUM CHLORIDE; PROTEIN ATG7; PROTEIN LC3 II; PROTEIN P62; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; ATG7 PROTEIN, MOUSE; ATXN3 PROTEIN, HUMAN; BECN1 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN; MUSCLE RELAXANT AGENT; NERVE PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BALANCE DISORDER; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FUNCTIONAL ASSESSMENT; MACHADO JOSEPH DISEASE; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; TREMOR; WEIGHT REDUCTION; ANIMAL; BODY EQUILIBRIUM; BRAIN; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; HUMAN; MACHADO-JOSEPH DISEASE; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXPLORATORY BEHAVIOR; HUMANS; LITHIUM CHLORIDE; MACHADO-JOSEPH DISEASE; MALE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEUROMUSCULAR AGENTS; NUCLEAR PROTEINS; POSTURAL BALANCE; REPRESSOR PROTEINS; TREATMENT OUTCOME; TREMOR; WEIGHT LOSS;

EID: 84911805605     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-014-0589-9     Document Type: Article

References (89)

1. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS drugs. 2006;20(1):29–42.
2. Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatr. 2003;64 Suppl 5:18–24.
3. Gao XM, Fukamauchi F, Chuang DM. Long-term biphasic effects of lithium treatment on phospholipase C-coupled M3-muscarinic acetylcholine receptors in cultured cerebellar granule cells. Neurochem Int. 1993;22(4):395–403.
4. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem. 1997;69(6):2336–44.
5. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455–9.
6. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 2001;280(3):720–5. doi:10.1006/bbrc.2000.4169.
7. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology. 2002;43(7):1173–9.
8. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacol (Berl). 2001;158(1):100–6. doi:10.1007/s002130100871.
9. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 1999;274(10):6039–42.
10. Hiroi T, Wei H, Hough C, Leeds P, Chuang DM. Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J. 2005;5(2):102–11. doi:10.1038/sj.tpj.6500296.
11. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2000;23(5):222–9.
12. Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem. 2000;275(11):7583–90.
13. Ren M, Senatorov VV, Chen RW, Chuang DM. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A. 2003;100(10):6210–5. doi:10.1073/pnas.0937423100.
14. Wei H, Leeds PR, Qian Y, Wei W, Chen R, Chuang D. Beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. Eur J Pharmacol. 2000;392(3):117–23.
15. Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci. 2008;28(12):3051–9. doi:10.1523/JNEUROSCI.5620-07.2008.
16. Jacobsen JP, Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res. 2004;1024(1–2):183–92. doi:10.1016/j.brainres.2004.07.065.
17. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989;59(3):411–9.
18. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv. 2004;4(5):259–72. doi:10.1124/mi.4.5.6.
19. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol. 2001;41:789–813. doi:10.1146/annurev.pharmtox.41.1.789.
20. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005;170(7):1101–11. doi:10.1083/jcb.200504035.
21. Sarkar S, Rubinsztein DC. Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy. 2006;2(2):132–4.
22. Melendez A, Hall DH, Hansen M. Monitoring the role of autophagy in C. elegans aging. Methods Enzymol. 2008;451:493–520. doi:10.1016/S0076-6879(08)03229-1.
23. Xu M, Zhang HL. Death and survival of neuronal and astrocytic cells in ischemic brain injury: a role of autophagy. Acta Pharmacol Sin. 2011;32(9):1089–99. doi:10.1038/aps.2011.50.
24. Rubinsztein DC. Autophagy induction rescues toxicity mediated by proteasome inhibition. Neuron. 2007;54(6):854–6. doi:10.1016/j.neuron.2007.06.005.
25. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007;6(4):304–12. doi:10.1038/nrd2272.
26. Lee SJ, Lim HS, Masliah E, Lee HJ. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res. 2011;70(4):339–48. doi:10.1016/j.neures.2011.05.008.
27. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42. doi:10.1016/j.cell.2007.12.018.
28. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–5. doi:10.1126/science.1101738.
29. Cuervo AM. Autophagy: in sickness and in health. Trends Cell Biol. 2004;14(2):70–7. doi:10.1016/j.tcb.2003.12.002.
30. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36(6):585–95. doi:10.1038/ng1362.
31. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 2009;16(1):46–56. doi:10.1038/cdd.2008.110.
32. Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet. 2002;11(9):1107–17.
33. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64(2):113–22.
34. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278(27):25009–13. doi:10.1074/jbc.M300227200.
35. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15(3):433–42. doi:10.1093/hmg/ddi458.
36. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain: J Neurol. 2010;133(Pt 1):93–104. doi:10.1093/brain/awp292.
37. Nascimento-Ferreira I, Santos-Ferreira T, Sousa-Ferreira L, Auregan G, Onofre I, Alves S et al. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain. 2011. doi:10.1093/brain/awr047.
38. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol. 2004;36(12):2445–62. doi:10.1016/j.biocel.2004.02.002.
39. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al. Macroautophagy—a novel beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol. 2005;171(1):87–98. doi:10.1083/jcb.200505082.
40. Menzies FM, Ravikumar B, Rubinsztein DC. Protective roles for induction of autophagy in multiple proteinopathies. Autophagy. 2006;2(3):224–5.
41. Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, et al. Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience. 2011;199:292–302. doi:10.1016/j.neuroscience.2011.10.031.
42. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6(12):1664–8.
43. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008;155(3):567–72. doi:10.1016/j.neuroscience.2008.06.040.
44. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML et al. Lithium delays progression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(6):2052-7. doi:10.1073/pnas.0708022105
45. Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington’s disease mutation. Brain Res Bull. 2003;61(4):375–83.
46. Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007;4(5):e182. doi:10.1371/journal.pmed.0040182.
47. Jia DD, Zhang L, Chen Z, Wang CR, Huang FZ, Duan RH et al. Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3beta in a SCA3 Drosophila model. Cerebellum. 2013. doi:10.1007/s12311-013-0498-3.
48. Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, Amorim M, Soares-Cunha C, Oliveira P et al. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 2014. doi:10.1007/s13311-013-0255-9.
49. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim. 2002;36(1):20–42.
50. Silva-Fernandes A, Costa MD, Duarte-Silva S, Oliveira P, Botelho CM, Martins L et al. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis. 2010. doi:10.1016/j.nbd.2010.05.021.
51. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome: Off J Int Mamm Genome Soc. 1997;8(10):711–3.
52. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci: Off J Soc Neurosci. 1999;19(8):3248–57.
53. Rafael JA, Nitta Y, Peters J, Davies KE. Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice. Mamm Genome. 2000;11(9):725–8. doi:10.1007/s003350010149.
54. JH Z. Biostatistical analysis (4th Edition). Prentice Hall; 1999
55. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4(2):151–75.
56. Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol Biol Cell. 2008;19(12):5360–72. doi:10.1091/mbc.E08-01-0080.
57. Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, de Burguera M, et al. Lithium and body weight gain. Pharmacopsychiatry. 1995;28(2):35–44. doi:10.1055/s-2007-979586.
58. Saute JAM, da Silva ACF, Souza GN, Russo AD, Donis KC, Vedolin L, et al. Body mass index is inversely correlated with the expanded CAG repeat length in SCA3/MJD patients. Cerebellum. 2012;11(3):771–4.
59. Lalonde R, Strazielle C. Brain regions and genes affecting limb-clasping responses. Brain Res Rev. 2011;67(1–2):252–9. doi:10.1016/j.brainresrev.2011.02.005.
60. Chou AH, Yeh TH, Ouyang P, Chen YL, Chen SY, Wang HL. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis. 2008;31(1):89–101. doi:10.1016/j.nbd.2008.03.011.
61. Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al-Mahdawi S, et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet. 2002;11(9):1075–94.
62. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506.
63. Fernagut PO, Diguet E, Bioulac B, Tison F. MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol. 2004;185(1):47–62.
64. Wirths O, Weis J, Kayed R, Saido TC, Bayer TA. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging. 2007;28(11):1689–99. doi:10.1016/j.neurobiolaging.2006.07.021.
65. Lalonde R, Dumont M, Staufenbiel M, Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res. 2005;157(1):91–8. doi:10.1016/j.bbr.2004.06.020.
66. Lalonde R, Lewis TL, Strazielle C, Kim H, Fukuchi K. Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. Brain Res. 2003;977(1):38–45.
67. Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: a user’s guide. Nat Rev Neurosci. 2009;10(7):519–29. doi:10.1038/nrn2652.
68. Riess O, Rub U, Pastore A, Bauer P, Schols L. SCA3: neurological features, pathogenesis and animal models. Cerebellum. 2008;7(2):125–37. doi:10.1007/s12311-008-0013-4.
69. Costa MD, Paulson HL. Toward understanding Machado-Joseph disease. Prog Neurobiol. 2011. doi:10.1016/j.pneurobio.2011.11.006
70. Matos CA, de Macedo-Ribeiro S, Carvalho AL. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Prog Neurobiol. 2011;95(1):26–48. doi:10.1016/j.pneurobio.2011.06.007.
71. Xiao H, Tang J, Hu Z, Tan J, Tang B, Jiang Z. [Polyglutamine-expanded ataxin-3 is degraded by autophagy]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010;27(1):23-8. doi:10.3760/cma.j.issn.1003-9406.2010.01.005.
72. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997;19(2):333–44.
73. Cheung ZH, Ip NY. Autophagy deregulation in neurodegenerative diseases—recent advances and future perspectives. J Neurochem. 2011;118(3):317–25. doi:10.1111/j.1471-4159.2011.07314.x.
74. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069–75. doi:10.1038/nature06639.
75. Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Haiem L, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci: Off J Soc Neurosci. 2004;24(45):10266–79. doi:10.1523/JNEUROSCI.2734-04.2004.
76. Schmitt I, Brattig T, Gossen M, Riess O. Characterization of the rat spinocerebellar ataxia type 3 gene. Neurogenetics. 1997;1(2):103–12.
77. Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust. 1981;1(8):407–9.
78. Gelenberg AJ, Jefferson JW. Lithium tremor. J Clin Psychiatry. 1995;56(7):283–7.
79. Bettencourt C, Santos C, Coutinho P, Rizzu P, Vasconcelos J, Kay T, et al. Parkinsonian phenotype in Machado-Joseph disease (MJD/SCA3): a two-case report. BMC Neurol. 2011;11:131. doi:10.1186/1471-2377-11-131.
80. Coutinho P, Sequeiros J. Clinical, genetic and pathological aspects of Machado-Joseph disease. J Genet Hum. 1981;29(3):203–9.
81. Ishida C, Sakajiri K, Yoshikawa H, Sakashita Y, Okino S, Yamaguchi K, et al. Lower limb tremor in Machado-Joseph disease. Neurology. 1998;51(4):1225–6.
82. Nandagopal R, Moorthy SG. Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3. Postgrad Med J. 2004;80(944):363–5.
83. Savvopoulos S, Golaz J, Bouras C, Constantinidis J, Tissot R. Huntington chorea. Anatomoclinical and genetic study of 17 cases. Encéphale. 1990;16(4):251–9.
84. Miodownik C, Witztum E, Lerner V. Lithium-induced tremor treated with vitamin B6: a preliminary case series. Int J Psychiatry Med. 2002;32(1):103–8.
85. Tremont G, Stern RA. Minimizing the cognitive effects of lithium therapy and electroconvulsive therapy using thyroid hormone. Int J Neuropsychopharmacol. 2000;3(2):175–86. doi:10.1017/S1461145700001838.
86. Grignon S, Bruguerolle B. Cerebellar lithium toxicity: a review of recent literature and tentative pathophysiology. Therapie. 1996;51(2):101–6.
87. Peiffer J. Clinical and neuropathological aspects of long-term damage to the central nervous system after lithium medication. Arch Psychiatr Nervenkr. 1981;231(1):41–60.
88. Niethammer M, Ford B. Permanent lithium-induced cerebellar toxicity: three cases and review of literature. Mov Disord. 2007;22(4):570–3. doi:10.1002/mds.21318.
89. Saute JA, Machado de Castilhos R, Monte TL, Schumacher-Schuh AF, Donis KC, D’Avila R et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Movement disorders: official journal of the Movement Disorder Society. 2014. doi:10.1002/mds.25803.